Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019
10. September 2019 05:14 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium
27. November 2018 04:47 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China
17. September 2018 06:58 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...